The first ready-to-eat weight loss pill is here! Lilly's Foundayo has received FDA approval, no fasting required, no waiting needed

Ask AI · How has the convenience of Foundayo changed the landscape of the oral weight-loss drug market?

Eli Lilly’s oral GLP-1 weight-loss drug Foundayo has received FDA approval, marking the beginning of a new phase in the global competition for weight-loss medications with oral formulations.

On April 1, Eli Lilly announced that this once-daily weight-loss pill called Foundayo is the only GLP-1 weight-loss medication that can be taken at any time during the day without dietary restrictions or water intake limitations.

In-stock products will be shipped via the LillyDirect platform, Eli Lilly’s direct-to-consumer sales platform, and will gradually be distributed to major U.S. pharmacies and telehealth platforms. Patients with insurance can pay only $25 per month using Eli Lilly coupons, while self-paying patients will pay between $149 and $349 depending on the dose.

According to Bloomberg’s compilation of Wall Street analyst forecasts, sales of Foundayo are expected to reach $18 billion by 2030. On Wednesday, Eli Lilly’s U.S. stock price intraday surged up to 6%, while competitor Novo Nordisk’s ADR had previously fallen by more than 2%.

(Eli Lilly closed up nearly 4% on Wednesday; Novo Nordisk’s ADR was up only about 1%, slightly lower)

Fast approval, trailing Novo Nordisk by about three months

Foundayo’s approval process took less than four months, thanks to the FDA’s fast-track review pathway specifically established for innovative drugs of national priority.

After Eli Lilly submitted the application this year, Foundayo’s launch was only about three months later than Novo Nordisk’s oral Wegovy, quickly shaping the competitive landscape.

In 2018, Eli Lilly acquired global rights to Foundayo’s active ingredient orforglipron from Japan’s Chugai Pharmaceuticals with a $50 million upfront payment.

Currently, Eli Lilly has stocked large inventories in advance to ensure rapid distribution and expects to obtain regulatory approvals in over 40 countries within the next year.

Since 2020, Eli Lilly has invested over $55 billion in manufacturing, including new and expanded production capacities.

Slightly less effective, but convenience and accessibility provide a differentiated advantage

Efficacy remains the core challenge for Eli Lilly.

In independent clinical trials, the oral Wegovy helped patients lose an average of approximately 13.6% of body weight over 64 weeks, while Foundayo’s weight loss ranged from about 11% to 12.4% (differences due to varying statistical methods).

In comparison, Eli Lilly’s injectable Zepbound achieves over 20% weight loss.

Nevertheless, doctors generally consider a weight loss of around 11% to be clinically significant.

Foundayo’s key advantage lies in its ease of use: patients can take it at any time during the day without fasting or water restrictions, whereas Wegovy oral must be taken on an empty stomach in the morning with only a small amount of water and requires waiting 30 minutes before eating.

Eli Lilly CEO Dave Ricks stated in an interview that injections have not become the main barrier to treatment adoption as initially expected, but he still views Foundayo as an important option for patients who prefer oral medication or seek lower prices.

Global expansion potential may be Foundayo’s biggest highlight

Foundayo and Zepbound differ fundamentally in product attributes.

Foundayo is a small-molecule compound, whereas Zepbound and Wegovy are peptide-based drugs; the latter’s manufacturing process is more complex and requires stricter cold chain logistics. This characteristic gives Foundayo a unique advantage for rapid global expansion.

Ricks said:

This enables large-scale production, allowing us to launch globally in sync from the first day. As long as we obtain regulatory approvals in various regions, we already have the capacity to supply oral GLP-1 inhibitors worldwide.

Currently, Wegovy oral is only sold in the U.S. and has not yet been introduced in other markets.

Ricks also pointed out that, as a small-molecule drug, Foundayo naturally avoids the competitive pressure from generic versions of Wegovy launched by competitors in some markets (including India), since the barriers for peptide drug generics are inherently higher.

Pricing is a key variable; Medicare coverage could unlock additional market demand

Regarding pricing, both drugs have the same starting dose price of $149 per month for self-pay patients, based on an earlier agreement between Eli Lilly and Novo Nordisk with the Trump administration.

Starting this summer, Medicare will cover elderly patients at a monthly cost of $50 for Foundayo and other GLP-1 weight-loss drugs, as part of this agreement. Ricks expects this program to generate “quite strong” demand, and these expectations are already incorporated into Eli Lilly’s full-year financial guidance.

Nidhi Kansal, an obesity specialist at the Northwest Medical Center, pointed out that price is the primary factor influencing current clinical decision-making. She said:

Unfortunately, in the decision-making process for doctors and patients, price is the main driver. Because these drugs are all excellent and we now have many options, but ultimately, it remains an economic decision.

BMO Capital Markets analyst Evan David Seigerman believes that the lower price threshold combined with the appeal of oral administration could attract potential patients who have been hesitant, further expanding the overall weight-loss drug market.

Foundayo’s approval is a key signal stabilizing Eli Lilly’s stock

Analysts generally agree that whether Foundayo can successfully increase volume sales is crucial for the future trajectory of Eli Lilly’s stock price.

So far this year, Eli Lilly’s stock has fallen about 14% from its recent high, after briefly surpassing a $1 trillion market cap, making it the first U.S. healthcare company to cross that milestone.

Cantor Fitzgerald analyst Carter Gould said that sales data lag behind actual demand, so the market will closely monitor prescription volumes to assess Foundayo’s market penetration speed. He said:

If prescription trends remain positive and continue to grow, I expect investors will tolerate some volatility in quarterly performance.

Meanwhile, the key clinical data readout for Eli Lilly’s more potent obesity injection, retatrutide, is also an important catalyst this year. Eli Lilly has disclosed some late-stage clinical data, but the core trial results specifically evaluating weight-loss efficacy have not yet been published.

Analysts believe that once the retatrutide data meets expectations, Eli Lilly will establish a comprehensive obesity treatment portfolio covering oral and injectable options across different efficacy levels.

FactSet data shows that analysts project sales by 2030 for Foundayo, Zepbound, and Mounjaro (approved in the U.S. for diabetes and in other markets for both diabetes and obesity) to be approximately $14.8 billion, $24.7 billion, and $44.9 billion, respectively.